Shin Poong Pharmaceutical Co., Ltd. exhibited at CPhI Worldwide 2017 in Frankfurt for their global marketing activity.

Shin Poong Pharmaceutical Co., Ltd. (CEO, Jei-Man, Ryu) participated in 'CPhI Worldwide 2017' held in Frankfurt, Germany from 24^th to 26^th of October. 

In the exhibition, about 40,000 pharmaceutical experts from 2,500 companies in 155 countries participated. Shin Poong focused on strengthening their global partnership to expand their global presence while grasping the global market trends of pharmaceutical industry. 

Shin Poong set a booth and received splendid responses by emphasizing on their global market entry of the new drug ‘Pyramax^®’ developed by Shin Poong’s own technology, along with the combination drugs, such as ‘Candeamlo^®’ and ‘Ezerosu^®’ which are the incrementally modified drug, and market expansion of surgical adhesion barrier ‘Medicurtain^®’. 

Shin Poong stated that “Despite the recent doldrums of the pharmaceutical market, the global BDs' enthusiasm for discovering new products with high technology was still hot. Through this exhibition, Shin Poong successfully promoted their distinctive and innovative technology, which attracted extraordinary interest of major companies from advanced and pharmersing countries such as Brazil, Turkey and Russia with many inquiry results”.

Shin Poong will continue to seek opportunities to enter into the global market through aggressive global marketing strategies as a global pharmaceutical company which researches and develops for the health of mankind.